Arcus Biosciences (NYSE:RCUS) Hits New 1-Year Low – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as $13.51 and last traded at $13.65, with a volume of 227874 shares changing hands. The stock had previously closed at $14.20.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RCUS. Wells Fargo & Company began coverage on Arcus Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. HC Wainwright restated a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a report on Wednesday, November 6th. Barclays raised their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Stock Up 2.9 %

The business has a fifty day moving average price of $15.74 and a two-hundred day moving average price of $15.95. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -4.51 and a beta of 0.87.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. During the same quarter in the prior year, the business earned ($0.94) EPS. The company’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, equities analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Insider Transactions at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 12.30% of the stock is currently owned by company insiders.

Institutional Trading of Arcus Biosciences

Large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences in the third quarter worth about $47,000. Point72 DIFC Ltd bought a new position in shares of Arcus Biosciences in the 2nd quarter valued at approximately $83,000. Quest Partners LLC raised its stake in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Arcus Biosciences in the 3rd quarter worth approximately $244,000. Finally, Martingale Asset Management L P bought a new stake in Arcus Biosciences during the third quarter worth approximately $251,000. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.